Mon, January 9, 2012
Sun, January 8, 2012
Sat, January 7, 2012
Fri, January 6, 2012
Thu, January 5, 2012
Wed, January 4, 2012
Tue, January 3, 2012
Mon, January 2, 2012
Sat, December 31, 2011
Fri, December 30, 2011
Thu, December 29, 2011
Wed, December 28, 2011
Tue, December 27, 2011
Mon, December 26, 2011
Fri, December 23, 2011
Thu, December 22, 2011
[ Thu, Dec 22nd 2011 ] - Market Wire
A View from the Top

Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference


//health-fitness.news-articles.net/content/2012/ .. 0th-annual-j-p-morgan-healthcare-conference.html
Published in Health and Fitness on Tuesday, January 3rd 2012 at 5:06 GMT by Market Wire   Print publication without navigation


Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference -- SAN DIEGO, Jan. 3, 2012 /PRNewswire/ --

Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference

[ ]

SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: [ OPTR ]) today announced that the Company will present at the 30th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10 at 8:30 AM Pacific Time.

(Logo: [ http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ] )

A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at [ www.optimerpharma.com ].   Replays of the presentation will be available at the same location for 30 days following the presentation.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in the European Union under the trade name DIFICLIR™. The company is seeking marketing authorization for fidaxomicin in Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at [ http://www.optimerpharma.com ].

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-909-0736

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005

 

SOURCE Optimer Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.optimerpharma.com ]


Publication Contributing Sources